1 I I Guidance Manual \H*1 Asbestos Operations & Maintenance Work Practices September 1992 The National Institute of Building Sciences (NIBS) is a non-governmental, non-profit organization, authorized by Congress to encourage a more rational building regulatory environment and to accelerate the introduction of existing and new technology into the building process.

NIOSH Appr val Lab I For R9722 ESCAPE ARTI TTM Mouthpiec Respirator Using R722 Ch mical Cartridg Permissible ESCAPE TYPE CHEMICAL CARTRIDGE RESPIRATOR FOR CHLORINE, HYDROGEN CHLORIDE, SULFUR DIOXIDE, CHLORINE DIOXIDE, HYDROGEN SULFIDE, DUSTS AND MISTS MINE SAFETY AND HEALTH ADMINISTRATION NATIONAL INSTITUTE OF OCCUPATIONAL SAFETY AND HEALTH ___ MSHA APPROVAL NO.

0001 1 IN THE UNITED STATES DISTRICT COURT 2 FOR THE NORTHERN DISTRICT OF ALABAMA 3 EASTERN DIVISION 4 5 CASE NUMBER: CV-98-C-0118-E 6 7 CECIL HINDS and RICHARD HINDS, 8 Plaintiff, 9 10 vs. 11 12 MONSANTO COMPANY, 13 Defendant. 14 15 STIPULATION 16 IT IS STIPULATED AND AGREED 17 by and between the parties through their 18 respective counsel that the deposition of 19 BRUCE ELEY may be taken before Tanya D. 20 Cornelius, Certified Shorthand Reporter 21 and Notary Public, at the law offices of 22 BURR & FORMAN, Birmingham, Alabama, on 23 the 7th day of October, 1999. 0002 1 IT IS FURTHER STIPULATED AND 2 AGREED that the signature to and the HINDS 10-07-1999 Eley, Brace.TXT[8/22/2017 4:46:02 PM] HARTOLDMON0033175 3 reading of the deposition by the witness 4 is waived, the deposition to have the 5 same force and effect as if full 6 compliance had been had with all laws and 7 rules of Court relating to the taking of 8 depositions. 9 IT IS FURTHER STIPULATED AND 10 AGREED that it shall not be necessary for 11 any objections to be made by counsel to 12 any questions, except as to form or 13 leading questions, and that counsel for 14 the parties may make objections and 15 assign grounds at the time of the trial, 16 or at the time said deposition is offered 17 in evidence, or prior thereto. 18 IT IS FURTHER STIPULATED AND 19 AGREED that notice of filing of the 20 deposition by the Commissioner is waived. 21 22 23 0003 1 INDEX 2 EXAMINATION BY: PAGE NUMBER: 3 Ms.

UUfIfvE.JV 1 NO. 90-1760-H 2 H.

IMPROVING DIALOGUE: A Case Study of the Community Advisory Panel of Shell Oil Company's Martinez Manufacturing Complex by Nevin Cohen Caron Chess Centerfor Environmental Communication Rutgers University Frances Lynn George Busenberg Department ofEnvironmental Sciences and Engineering University ofNorth Carolina, Chapel Hill August 1995 WppWI||BBW|l!

CONFIDENTIAL World Register of Cases of ANGIOSARCOMA OF THE LIVER (ASL) due to VCM REVIEW DATE 1st JANUARY 1990 ********* Collated toy: Or Brian Bennett Occupational Health ICI Chemicals and Polymers Ltd Hillhouse Site PO Box 4 Thornton-Cleveleys (Telephone Blackpool FY5 400 (Telex England (Fax 0253 861632 J 67483ICIPLH6) 0253 86iB6i ) CMA 010700 LIVER ANGIOSARCOMA CASES circulation of register CONFIDENTIAL FE3RUARY 1390 BAGSHAW Dr I M M BAND Dr P R BARRAT Dr G BAXTER Dr P BAYLAC Dr BELLEC Dr BENECH Dr M BENNETT Dr B BERTAZZI Dr P BERTUZZI M BEYNON D W S BISHOP Dr C BORRELLI F E BRAUN Dr C L J BROGDEN M E BROWN Dr M G BYREN Dr David CAMPION Dr Catherine CARTER Dr J T CATANZARITI A CELLA C CHANCE M CLARKE Dr E A CLAYTON H CONTASSOT Dr J C DAVIES J G DELORME Dr F DEPLAN Dr F DIETZ Dr H W DOLL Prof Sir Richard DOMBROWSKI S L S DOORNBOS Dr N DRUMWRIGHT Dr J R DUPONT G EMMINGER H ERNST Dr W EVANS Dr A E J FALK Dr H FARMERY Dr K FAVRE Dr FIELDING Miss C Hydro Polymers Ltd, Newton Aycliffe, UK Cancer Control Agency of British Columbia, Vacouver, Canada AECRP, Commentry, France University of Cambridge UK Atochem, Chauny, France Rhone Poulenc, Aubervillers, France Naphtachimie, Lavera, France ICI Hillhouse, UK Inst of Occupational Health, Milan University, Italy EVC, Brussels, Belgium ICI Runcorn, UK EMAS, Cardiff, UK Georgia Gulf, Delaware City, USA Akzo, Arnhem, The Netherlands ICI Runcorn, UK Shell, An Den Haag, The Netherlands Nobel Industrier, Sundsvall, Sweden Health & Safety Executive, Bootle, UK EMAS, London, UK EVC, Brussels, Belgium EVC, Brussels, Belgium ICI Runcorn, UK Ontario Cancer Foundation, Toronto, Canada Norsk Hydro, Newton Aycliffe, UK Atochem, Saint-Fons, France EVC, Brussels, Belgium Quebec, Canada Atochem, Jarrie, France B F Goodrich, Akron, Ohio, USA Imperial Cancer Research Fund, Oxford University, UK Dow Chemical, Midland, Michigan, USA DSM, Beek, The Netherlands Vista Chemical, Houston, Texas, USA APME, Brussels, Belgium VKE, Frankfurt, Germany Berufsgenossenschaft der Chemischen Industries, Nurnberg, Germany Lever Bros, Warrington, UK Centers for Disease Control, Atlanta, Georgia, USA ICI Hillhouse, UK Atochem, Montluel, France ICI Millbank, London, UK CMA 010701 J FILLINGER J FINCHAM Ms Shirley FOA Prof V FORMAN Dr D FRASE R W FREIESLEBEN Dr W FRIEDEL Dr H P GAFFEY Dr W GIUDICE Dr S GOTTESMAN Dr R T GROISMAN D HILLMAN Dr D W HOWARD Dr J K HOWE Dr W HUMPHRY Dr N F JOHNSON Dr C A JOHNSON Roy N KAIPERT Dr J H KALNAS Dr J KLEIN Dr H LAGAST Dr H LANHAM Dr John LANOUZIERE Dr Claudine LAWRENCE-JONES Sir C LEE Dr F I LEESER Dr Jenny LELBACH Prof Dr WK LEVEQUE Dr G LEVISON Prof Dr D A LEWIS Dr P LIGO Dr R N LO MARTIRE Prof N LUSS R D LUSSATO Dr Josette MALTONI Prof C MATTIUSSI Dr R MELTON B MIDDLETON D MOKKA Mr MONTESANO Dr R MOTTI Dr A A MUNOZ MOUTON Dr M MacSWEEN Prof RNM NAKAMURA Dr S OSMAN Dr J PADDLE Dr G M -2 Solvay, Brussels, Belgium Alberta Cancer Board, Edmonton, Canada Inst Industrial Medicine, Milan, Italy Imperial Cancer Research Fund, Oxford University, UK DiversiTech General, Akron, Ohio, USA ECVM, Brussels, Belgium Berufsgenossenschaft der Chemischen Industries, Heidelberg, Germany Monsanto Co, St Louis, Missouri, USA Montedipe, Venice, Italy The Vinyl Institute, Wayne, NJ, USA Electrochemical Industries, Acre, Israel Diamond Shamrock Corp, Dallas, Texas, USA University of Otago School of Medicine, Wellington, New Zealand ICI Runcorn, UK ICI Australia, Melbourne, Australia Goodyear Tire and Rubber, Akron, Ohio, USA GenCorp, Fairlawn, Ohio, USA Dow Chemical Europe, Horgen, Switzerland Imperial Oil, Sarnia, Ontario, Canada Dynamit Nobel, Troisdorf, Germany Solvay, Brussels, Belgium Dow Chemical, Midland, Michigan, USA Solvay, Tavaux, France Chief Medical Officer, ICI, London, UK Victoria Hospital, Blackpool, Lancs, UK ICI Runcorn, UK University of Bonn, West Germany CDF Chimie, AZF, Bully-les-Mines, France Guy's Hospital, London, UK Chemical Industries Association, London, UK Dupont, Wilmington, Delaware, USA EniChem, Milan, Italy Occidental Chemical, Pottstown, Pennsylvania, USA Atochem, Port de Bouc, France Institute di Oncologia, Bologna, Italy Montedison, Milan, Italy Formosa Plastics, Delaware City, USA Hydro Polymers Ltd, Newton Aycliffe, UK Neste Oy, Espoo, Finland IARC, Lyon, France ICI Duperial, Buenos Aires, Argentina Rio Rodano, Madrid, Spain Western Infirmary, Glasgow, Scotland Japanese PVC Association, Tokyo, Japan Health & Safety Executive, Bootle, UK ICI Central Medical Group, Alderley Park, UK CMA 010702 3 PAQUET Dr Christiane PATERSON Dr J C PIRASTU Dr Roberta POSSBERG Dr J PUECH Dr A M PURDHAM Dr J RAMBAUD Dr J RICHARD Dr A ROBSON Mrs D ROSA Dr HS RUTY Dr J SALG Dr Joyce A SCHIPPER Dr H SCHUCKMANN Dr F SERONNE Dr D SHAH Dr Has SIGRIST Dr J SMITH Prof Allan H SMITH Dr P M SPIRTAS Dr R STAFFORD Dr J STAHNECKER Dr E SULAIMAN Dr TACHECI Dr H TAMBURRO Prof CH TENKHOFF Dr N TEPPER Dr L B TERWIESCH Dr B THERIAULT Dr Gilles THUS - EVENSEN Dr E THOMSON Dr D H TOMATIS Dr L TONER H P VAN DER MERWE Dr H J WALTEMATE H WEJDLING S 0 WILLIAMS Dr DMJ WILSON Prof R YORK J ZOBER Dr M A Atochem, Serquigny, France ICI Runcorn, UK Istituto Superiore di Sanita, Rome, Italy Wacker-Chemie, Munich, Germany Atochem, Brignoud, France University of Toronto, Ontario, Canada RP Recherches, Antony, France Rhone Poulenc, Roussillon, France Saskatchewan Cancer Foundation, Regina, Canada Petroquimica, Salvador, Brazil Atochem, St Auban, France NIOSH, Cincinnati, Ohio, USA University of Manitoba, Winnipeg, Canada Hoechst, Frankfurt, Germany Diamond Shamrock, Dallas, USA CMA, Washington DC, USA Shell Chimie, Berre L'Etang, France University of California, Berkeley, USA Llandough Hospital, Penarth, UK NCI/NIH, Bethesda, Maryland, USA Somerset, UK BASF, Ludwigshafen, Germany Arabian Petrochemical Co, Saudi Arabia Hoechst AG, Frankfurt, Germany _ University of Louisville, Kentucky, USA Huls AG, Marl, Germany Air Products, Allentown, Pennsylvania, USA Huls AG, Marl, Germany McGill University, Montreal, Canada Norsk Hydro, Porsgrunn, Norway Cancer Treatment & Research Foundation, Halifax, NS, Canada IARC, Lyon, France Society of the Plastics Industry, Washington DC, USA AECI, Sasolburg, South Africa BF Goodrich, Cleveland, Ohio, USA Norsk Hydro, Stenungsund, Sweden BP Chemicals International, Barry, UK Harvard University, Cambridge, Massachusetts, USA EVC, Brussels, Belgium BASF, Ludwigshafen, Germany From: Dr B Bennett, Occupational Health, ICI Chemicals & Polymers, Hillhouse Site,PO Box 4, Thornton-Cleveleys, Blackpool, FY5 4QD England CMA 010703 CONFIDENTIAL register of cases of angiosarcoma of the liver due to exposure to vinyl chloride - REVIEW DATE 1 JANUARY 1990 PREFACE : ACKNOWLEDGEMENTS, SIGNIFICANT CHANGES, COMMENTS AND REQUESTS 1 The 14 new cases in this Register are: France 26, 27, 28; Germany 33, 34, 35, 36, 37, 38, 39; Spain 01; UK17, US 42,43.

SET Standard DATE December 30 1996 COMES NOW defendant Kaiser Gypsum Company Inc. hereinafter 20 Kaiser Gypsum and provides the following updated responses to 21 plaintifs pplaintiffs laintiffs standard interrogatories propounded pursuant to San 22 Francisco County Complex Asbestos Litigation General Order No. 29 29 KAISER GYPSUM'S PRELIMINARY STATEMENT AND OBJECTIONS 24 Kaiser Gypsum was constituted in 1952 and has been 25 headquartered in California since that date Kaiser Gypsum 26 disposed of its last operating manufacturing plant in August 1978 27 and subsequently has not engaged in manufacturing or product sales 281 anywhere in the United States Thus all Kaiser Gypsum product sales occurred between 1952 and 1978 Therefore Kaiser Gypsum's responses to plaintiffs standard interrogatories are based almost entirely on its ongoing review of documents presently available to the These updated interrogatory responses reflect Kaiser Gypsum's knowledge at this time and supersede any previous interrogatory answers Kaiser Gypsum reserves the right to further supplement these responses in the event that more complete or accurate information becomes available Kaiser Gypsum notes that these responses are made without reference to the factual circumstances of any particular case and accordingly Kaiser Gypsum reserves the right to state additional objections or provide supplemental responses that might be appropriate in the specific context of a given plaintiff's claim Kaiser Gypsum objects to requests for information that are unlimited as to geographical scope on the grounds that such requests are unduly burdensome and are not reasonably calculated to lead to the discovery of evidence admissible in cases that are 19 subject to General Order No. 29.

DOW CONFIDENTIAL ' INFORMATION Do not copy When no X longer needed: Return to La.

;>Vs /.

1 r' (\ \ 1 UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT X NEVADA POWER COMPANY, a Nevada Corporation, Plaintif f , vs.

December 6, 1995 Dr.

CONFIDENTIAL World Register of Cases of ANGIOSARCOMA OF THE LIVER (ASL) due to VCM REVIEW DATE 1st JANUARY 1990 ********* Collated by: Or Brian Bannatt Occupational Health ICI Chemicals and Pi Hillhousa Site PO Box 4 Thornton-Cla velays Blackpool FY3 400 England wars Ltd (Telephone (Telex (Fax 0253 861632 J 67483 ICIPLH6) 0253 B61861 J C0j:,7J-7>T "TIATi SuViest"-.) r.-; Ross v.

Final Report Review Date .Inspected Date Reported to Date Reported to Exygen Study Director Management 10/10/02 10114102 10/30/02 Date Reported to Sponsor 10/30/02 10115102 10125-28/02 10125102 10129/02 10125102 10130/02 10/30/02 10130/02 10130102 10/30/02 10/30/02 10/30/02 Naomi Lovallo Technical Lead-QA Date .

' 9 Kaiser Gypsum notes that these responses are made without 10 reference to the factual circumstances of any particular case, 11 and, accordingly, Kaiser Gypsum reserves the right to state 12 additional objections or provide supplemental responses that might 13 be appropriate in the specific context of a given plaintiff's 14 claim(s). 15 Kaiser Gypsum objects to requests for information that are 16 unlimited as to geographical scope on the grounds that such ]_7 requests are -unduly burdensome and are not reasonably calculated 18 to lead to the discovery of evidence admissible in cases that are A. 19 subject to General Order No. 29.

FINAL REPORT RECEIVED 0PPT CBIC 20FEB 22 A411: 34 PROTOCOL 418-014 ORAL (GAVAGE) CROSS-FOSTERING STUDY OF PFOS IN RATS SPONSOR'S STUDY NUMBER: T-6295.13 FINAL REPORT DATE: 23 JULY 1999 245 40975 um PROTOCOL 418-014 ORAL (GAVAGE) CROSS-FOSTERING STUDY OF PFOS IN RATS SPONSOR'S STUDY NUMBER: T-6295.13 SUBJECT TAOFBCONLTENETS ' SUMMARY AND CONCLUSION A.